Company Overview
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -171.2%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -171.21% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +133.12% |
| 6 Months: | -15.36% |
| 3 Months: | +2.67% |
| 1 Month: | +0.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -171.2% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | SRRK Scholar Rock Holding Corporation R2K | 47.87 | -13.88 | $5.74B | 0.00% | -110.26% | -138.94% | - | - |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 15.52M | 17.60M | 23.02M | 28.08M | 32.68M |
| Operating Income | - | -15.52M | -17.60M | -23.02M | -28.08M | -32.68M |
| EBITDA | - | -15.52M | -17.60M | -23.02M | -21.36M | -32.68M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -14.28M | -16.32M | -21.69M | -25.32M | -26.94M |
| Tax Provision | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | - | -14.28M | -16.32M | -21.69M | -25.32M | -26.94M |
| Diluted EPS | - | -0.45 | -0.50 | -0.65 | -0.70 | -0.68 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 12.82M | 31.67M | 40.00M | 84.21M |
| Operating Income | -12.82M | -31.67M | -40.00M | -84.21M |
| EBITDA | -12.43M | -31.20M | -35.67M | -77.14M |
| Interest Expense | 16.00K | 25.00K | 20.00K | 2.00K |
| Pretax Income | -12.65M | -31.62M | -36.14M | -77.61M |
| Tax Provision | 0 | 9.00K | 6.00K | 0 |
| Net Income | -12.65M | -31.63M | -36.14M | -77.61M |
| Diluted EPS | -0.63 | -1.19 | -1.18 | -2.31 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 44.27M | 94.64M | 152.13M | 780.56M |
| Current Assets | - | 42.81M | 89.94M | 147.07M | 494.27M |
| Cash & Equivalents | - | 42.09M | 88.16M | 31.68M | 352.93M |
| Inventory | - | - | - | - | - |
| Receivables | - | 19.00K | 867.00K | 594.00K | 718.00K |
| Total Liabilities | - | 2.77M | 4.21M | 6.31M | 10.07M |
| Current Liabilities | - | 2.10M | 3.63M | 6.05M | 9.88M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 866.00K | 886.00K | 537.00K | 429.00K |
| Total Equity | - | 41.50M | 90.43M | 145.82M | 770.49M |
| Shares Outstanding | - | 24.90M | 29.18M | 31.86M | 39.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -11.46M | -29.84M | -29.23M | -36.99M |
| Investing Cash Flow | - | -394.00K | -63.00K | -110.57M | -305.11M |
| Financing Cash Flow | - | 36.96M | 75.96M | 83.59M | 663.23M |
| Capital Expenditure | - | -394.00K | -63.00K | -151.00K | -178.00K |
| Free Cash Flow | - | -11.85M | -29.90M | -29.39M | -37.17M |
| Net Change in Cash | - | 25.11M | 46.06M | -56.21M | 321.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -30.5% | -35.0% | -24.8% | -10.1% |
| ROCE % | -30.4% | -34.8% | -27.4% | -10.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Darwin Global Management, Ltd. | 7.63% | 3.06M | $484.60M |
| 2 | Paradigm Biocapital Advisors LP | 2.78% | 1.11M | $176.69M |
| 3 | UBS Group AG | 1.92% | 768.36K | $121.78M |
| 4 | RTW Investments LP | 1.78% | 715.33K | $113.38M |
| 5 | Millennium Management Llc | 1.42% | 570.09K | $90.36M |
| 6 | Holocene Advisors, LP | 1.23% | 494.50K | $78.38M |
| 7 | Eventide Asset Management LLC | 0.89% | 357.65K | $56.69M |
| 8 | Deerfield Management Company, L.P | 0.76% | 304.01K | $48.19M |
| 9 | Price (T.Rowe) Associates Inc | 0.70% | 281.81K | $44.67M |
| 10 | Morgan Stanley | 0.50% | 201.41K | $31.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLTE
Tinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20% - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPXzB5NzJheExNRkt3VTNuN3QyMWdpWFBuQUJHaVpMLTJlVm44YkNVOTdpUWlycG0xcDBfQ0lKWU9zS0xZdlczMVVPUk1KbFd3OWVIMy1sR1BHeTFjOTZzS1JoSGUwRmFKek9KQVhNZ2RMOHpDbGZ2S2VyZ0gyYlV4Sk9tRVpYeGFTajRnU0…
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWTZmYjJGY3UtQmZEcGtvUHRjRXZIcmp5X2oyZ1B3dWxGOVJqUGJHby1RLXoyVkZja0lyQkJiVUhlSFEyQlBvVmN6WTgtdkdZZ3VnU3dmOUhtSzkxbExnWEVIZjVGbDdCdkRKcTdUdlhqZ0VHTDM0QWpVaXZYM0h6bTA3UWpqUzNZY0lkTG…
Belite Bio: The Oral Route Is The Real Competitive Moat (NASDAQ:BLTE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQaHFON2Q3TmUyTXJpQzUxWE1IRDJ4cHdpYXhrRXJDSm5OdmFucDVNRGZjaXBxamJxRHJNWlRaenJpYS1UV2JFUnhoSW1kWXFTbHFrNzBxVmlPNHgzNDhuYjc1YUpZLUxOT0RjeFNpVmFSaVRiRE8wMUtuVW54cjNndDBtV1lyd3VhcXFkSz…
Insider Sale: Chief Medical Officer of $BLTE Sells 540 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQcENNd0VVclhhQnE1dWVYYlBZTklHWEM2LTkzYUwtbW9KU0NvM01tajVpNjBhWGhuUzRVejVPSnUtNklUN0FXcGJ5bGNUUWo4ZHlGaEZxYmFscUJEVnppZm03dFQ1ZWxLeHFWRWRkd1gwRnJnVGlGTGFBOGVXVkdpYm01TnB0a2NzUU9mTT…
(BLTE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPY05mTXdkV1M3QUxub1RzTFJlM2x3MW9Yb1QwQjZUaXNsWWZTTk5YV1dHQ0tuLVZVQ3RGZUFxR2pqdkhlQWRHNExNVHVJMm9lY1E3NVFtYmdOSlpqclJyazRlVG1yQWh2T3NDY0xCcEhnSnNMV2Z6Q2VIdEcycWczZXVxUG9LVDJiaTNTWE…
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQMHpDLXBNa2VYbUZId1luWnVudFgzUXFXUFpwV2doLVYzVVJzWEEtcDRqOUtmSW9jM0NSQi1JM1FaQnRaSURrX3pkTjRfNXdSVVZUamkzS0U4VnlwQkt3c1pkOTRwRFdWWm9DQzBmUlRPcGFEd3hmcUF5QkNHcGFVeA?oc=5" target="_…
BLTE — Frequently Asked Questions
What is the current share price of Belite Bio, Inc (BLTE)?
As of 2026-08-05 17:25 PDT, Belite Bio, Inc (BLTE) trades at $158.50 on NasdaqCM. Its 52-week range is $61.81 to $190.30.
What is the market capitalisation of BLTE?
Belite Bio, Inc (BLTE) has a market capitalisation of $6.35B on NasdaqCM.
What is the P/E ratio of BLTE?
BLTE trades at a trailing price-to-earnings (P/E) ratio of -62.16. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 7.84.
What is the return on equity (ROE) of BLTE?
BLTE has a return on equity (ROE) of -18.93%. Its return on capital employed (ROCE) is -10.07%.
Is BLTE a good stock to buy?
This page provides a data-driven analysis of Belite Bio, Inc (BLTE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.